DSGN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
22.2M
+12.5%
19.7M
+8.5%
18.2M
-5.9%
19.3M
-10.5%
21.6M
R&D
16.4M
+14.0%
14.4M
+7.1%
13.4M
-8.0%
14.6M
-7.3%
15.7M
SG&A
5.8M
+8.7%
5.3M
+12.3%
4.7M
+0.5%
4.7M
-19.0%
5.8M
Operating Income
-22177000
-12.5%
-19706000
-8.5%
-18169000
+5.9%
-19311000
+10.5%
-21569000
EBITDA
-22026000
-12.7%
-19549000
-8.5%
-18013000
+6.0%
-19156000
+10.6%
-21417000
Net Income
-20165000
-14.3%
-17636000
-10.2%
-15997000
+5.9%
-16997000
+10.9%
-19083000
EPS (Basic)
$-0.32
-10.3%
$-0.29
-7.4%
$-0.27
+10.0%
$-0.30
+11.8%
$-0.34
EPS (Diluted)
$-0.32
-10.3%
$-0.29
-7.4%
$-0.27
+10.0%
$-0.30
+11.8%
$-0.34
Shares (Diluted)
62.5M
+1.7%
61.4M
+4.6%
58.8M
+3.2%
57.0M
+0.2%
56.9M
Design Therapeutics (DSGN) โ€” Financials